Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Uterine Neoplasms 1Tuberous Sclerosis 1Perivascular Epithelioid Cell Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Angiomyolipoma 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × dactolisib × Clear all
NCT01288092 2012-06-07

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Novartis

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡